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Objective: To report on the relative cost-effectiveness
of total hip arthroplasty and resurfacing arthroplasty
(replacement of articular surface of femoral head only)
in patients with severe arthritis suitable for hip joint
resurfacing arthroplasty.
Design: Cost-effectiveness analysis on an intention-to-
treat basis of a single-centre, single-blind randomised
controlled trial of 126 adult patients within 12 months
of treatment. Missing data were imputed using multiple
imputations with differences in baseline quality of life
and gender adjusted using regression techniques.
Setting: A large teaching hospital trust in the UK.
Participants: A total of 126 adult patients with severe
arthritis of the hip joint suitable for a resurfacing
arthroplasty of the hip.
Results: Data were received for 126 patients, 4 of
whom did not provide any resource use data. For the
remainder, data were imputed for costs or quality of life
in at least one time point (baseline, 3, 6 months and
1 year) for 18 patients. Patients in the resurfacing arm
had higher quality of life at 12 months (0.795 vs 0.727)
and received 0.032 more QALYs within the first
12 months postoperation. At an additional cost of £564,
resurfacing arthroplasty offers benefits at £17 451 per
QALY within the first 12 months of treatment. When
covariates are considered, the health economic case is
stronger in men than in women.
Conclusions: Resurfacing arthroplasty appears to offer
very short-term efficiency benefits over total hip
arthroplasty within a selected patient group. The short-
term follow-up in this trial should be noted, particularly
in light of the concerns raised regarding adverse
reactions to metal debris from metal-on-metal bearing
surfaces in the longer term. Longer-term follow-up of
resurfacing arthroplasty patients and decision analytic
modelling is also advised.
Trial registration: Current controlled Trials
ISRCTN33354155. UKCRN 4093.
INTRODUCTION
Hip arthroplasty is acknowledged to be a
highly effective and cost-effective procedure
for treating patients with severe arthritis of
the hip joint, with 87% of patients reporting
an improvement in their general health
following surgery.1 The total health gain is
expected to be substantial given the effective-
ness of treatment; EuroQol (EQ-5D-3L)-
based quality-of-life improvements following
surgery are estimated to be 0.409, within the
45 000 cases measured in the UK Patient
Reported Outcomes programme.2 A total of
97% of UK hip replacements are still
working (unrevised) at 5 years3 and 83% of
all primary hip arthroplasty (all age and all
implant types) are unrevised at 17 years post-
surgery in Sweden.4 If the initial quality-
of-life gains are maintained, each unrevised
surgery represents over ﬁve discounted
ARTICLE SUMMARY
Article focus
▪ This article compares the cost-effectiveness of
hip resurfacing as against conventional hip
arthroplasty surgery.
▪ The findings are based on data from an RCT
conducted within a single, UK centre.
▪ The analysis considers outcomes within the first
year of initial surgery.
Key messages
▪ Within the first year of treatment, hip resurfacing
appears cost-effective.
▪ The choice of arthroplasty implant appears a key
driver of this judgement.
▪ The evidence for resurfacing appears stronger
for male than female patients.
Strengths and limitations of this study
▪ This article provides the first within-trial data on
the cost-effectiveness of resurfacing.
▪ The period considered here cannot capture
important issues (eg, long-term survival of
metal-on-metal resurfacing implants versus hip
arthroplasty implants).
▪ The findings merit further analysis and explor-
ation within a decision analytic model.
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quality-adjusted life-years (QALYs) gained and a beneﬁt
of over 100 000 pounds at the £20 000 per QALY thresh-
old used by the National Institute of Health and Clinical
Excellence (NICE). Compared to these gains, the costs
of hip arthroplasty surgery appear modest. As a result,
most analyses considering health economics have con-
centrated on questions of which type of prosthesis to
use, and many cost-effectiveness analyses have involved
analysis of newer, more expensive operations against
older, established comparators.5–7 Resurfacing arthro-
plasty (RSA) of the hip is a newer alternative form of
arthroplasty designed for younger, active patients with
severe arthritis of the hip.
Hip RSA involves the insertion of an acetabular com-
ponent and the ‘capping’ of the femoral neck, rather
than its removal and replacement with a femoral compo-
nent in a standard total hip arthroplasty (THA). Of the
70 000 hip arthroplasty operations conducted in
England and Wales every year,3 approximately 6% are
hip resurfacings. The equivalent ﬁgure among men
aged under 55 is 33%. As resurfacing preserves the bone
of the proximal femur, it may be expected to provide
better clinical outcomes on revision of this component
than available with a standard hip arthroplasty. Despite
advances in their construction, there are still questions
about the durability of modern resurfacing implants and
there have been few explicit economic evaluations com-
paring resurfacing arthroplasties against total hip arthro-
plasties.8 9 Few randomised controlled trials have been
conducted to assess the outcomes of hip resurfacing,
and those that exist provide little detail about the eco-
nomic costs and beneﬁts within the initial year following
surgery. This paper reports the ﬁrst within-trial eco-
nomic evaluation of RSA versus THA.
METHODS
Interventions and sample
This evaluation reports on the efﬁciency of RSA versus
THA. Patients were deemed eligible for the trial if they
were aged over 18 years of age, were medically ﬁt for an
operation and were deemed suitable to receive an RSA.
Patients were only excluded from the study if there was
evidence that the patient would be unable to adhere to
trial procedures or complete questionnaires. Patients
were randomised on a 1:1 basis between THA and RSA,
with each patient operated on according to the preferred
technique of the operating surgeon. Other perioperative
interventions, such as prophylactic antibiotics and
thrombo-prophylaxis were the same for all patients and
the same standardised rehabilitation plan was employed
for both trial arms. Further details on recruitment,
ethics and randomisation procedures are reported in
both the randomised controlled trial’s (RCT) protocol
and reporting papers.10 11 The main outcome measure
of the trial was hip function (Oxford Hip Score; Harris
Hip Score) at 12 months, and the trial found no evi-
dence of a difference between RSA and THA.
Perspective
The aim of the economic study is to determine the inter-
vention that would maximise health outcomes within
the limited National Health Service (NHS) budget in
this period, and so a cost-effectiveness (cost-utility) ana-
lysis with an NHS and Personal Social Services (PSS)
perspective is adopted in the base case. This paper con-
siders the within-trial period (as intention to treat) of
the ﬁrst 12 months of follow-up. It considers only
resources used within the NHS setting including any
aids and adaptations required. The base year for all costs
ﬁgures was 2009/2010, with ﬁgures from other years
converted using the hospital and community health ser-
vices Pay and Prices Index (for adults, excluding
capital).12 For current costs, ﬁgures are deﬂated assum-
ing an estimated inﬂation rate of 1.9% to 2010 from this
index for both 2009/2010 and 2010/2011. As the ana-
lysis uses a 1-year time horizon, discounting for the
future cost and health outcome is not necessary in this
analysis. The currency used was the pound sterling (£).
Quality of life
Responses from the EQ-5D-3L were obtained from
patients at baseline, 3, 6 and 12 months, respectively, as
secondary outcomes of the trial10; results from other
outcomes are reported in greater depth elsewhere.11
The standard tariff values13 were applied to these
responses at each time point to provide EQ-5D-3L
quality-of-life values. QALYs were calculated as an ‘area
under the curve’ and form the main outcome measure
of the study. Where comparisons between the RSA and
THA arms are based on non-imputed data, a two-sample
t test assuming equal variances is used.
Resource use and valuation
The costs of THA and RSA treatments were considered
across six broad categories—the costs of the initial oper-
ation, of inpatient care postdischarge, of outpatient
care, of primary/community care, and of medications,
and aids/adaptations required while in the community.
The analysis considered inpatient and outpatient atten-
dances for all reasons, and requested details of other
resource usage only where it related to pain or hip
surgery.
All RSA patients received a Cormet metal-on-metal
(MOM) resurfacing (Corin Group, Cirencester, UK),
while THA patients received their surgeon’s preference
of prosthesis. For the patients having THA the prosthesis
type was identiﬁed from patient records, with three types
of bearing surface (ceramic femoral head on ceramic
socket, MOM and metal-on-polyethylene) accounting for
95% of cases. The University Hospitals Coventry and
Warwickshire NHS Trust Finance Department provided
implant list prices for both the resurfacing implant and
representative cost ﬁgures for these three types of pros-
thesis. In the remaining 5% of cases, implant type was
treated as missing and were imputed to fall in one of
these groups.
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The current Healthcare Resource Group v.4 (HRG4)
reference costs include the cost of prosthesis across all
ages, and in most cases this will be a THR as HRG4 does
not include a single category for primary replacements
(as appeared in previous versions). Identiﬁed national-
level HRG4 frequencies for primary hip replacements
are available14 and these are used to calculate an
average cost, average length of stay and average cost per
excess bed day. By deducting the expected THA cost
from the average cost, we obtain a non-prosthesis
average cost, to which it is possible to add the appropri-
ate prosthesis cost relevant to each individual. From
here, an average cost of the initial hospitalisation is cal-
culated for each patient by adjusting for each patient’s
length of stay (as a number of bed days from the mean).
In this way, a person admitted for the average length of
stay would be assigned the average cost of treatment,
with those staying shorter and longer periods assigned
lower and higher costs, respectively.
Data regarding length of stay and implant received were
obtained from hospital records, with the remainder of the
costing information obtained from patient-reported data.
Resource usage was assessed alongside other outcomes at
3, 6 and 12 months, respectively. For the 3-month data, the
recall period was since discharge from hospital. For the
other cases, it was since the last questionnaire was due to
be completed. The questionnaires included sections on
further inpatient care following the initial operation (spe-
cialty and length of stay/day case), outpatient care,
primary and community care, aids and adaptations pro-
vided by the NHS/social services and medication (pain
relief and other NHS medication). Medicines usage was
estimated based on mean dosage when used and average
usage within the three budgetary periods (discharge to 3,
3–6 and 6–12 months, respectively). In order to convert
resource usage ﬁgures into costs, unit cost ﬁgures were
assigned from NHS reference costs,15 Personal Social
Services Research Unit (PSSRU) unit costs,12 NHS elec-
tronic drug tariff16 and reported unit costs of acupuncture
and chiropractic from previous studies. Individual
resource items and unit prices, including for aids and
adaptations, are available in Tables provided as a Web
Extra. Where statistical tests analyse resource usage data, t
tests are used to test for differences in expected usage
(assuming equal variance and non-imputed data).
Data on personal costs (out of pocket medicine usage
and time off work for either the patient or a carer) were
also collected. NHS unit costs were used to provide an
indicative ﬁgure for private medicines costs, while 2009
median gross weekly earnings from full time jobs
(£488.70) was used to identify a daily productivity cost of
£97.74. These are used in the sensitivity analysis consid-
ering societal costs.
Missing data
Where data were incomplete we used multiple imput-
ation via chained equations (ice)17 to complete missing
data using STATA V.11 (StataCorp 2009, Texas,
USA).18 19 Missing cost data were predicted in terms of
QALYs, treatment received, length of stay, age, gender,
height, weight and baseline clinical scores (Oxford Hip
Score, Harris Hip Score); missing QALY data were pre-
dicted in terms of this same list (excluding QALYs), plus
each of the cost items; missing length of stay was pre-
dicted using the same list as for QALYs, with QALYs
included. In order to remove implausible data, missing
cost data were constrained to be positive and length of
stay was constrained to be at least three days postimputa-
tion. A total of 50 imputations were used to inform each
item of missing data. Where tests are conducted to
detect signiﬁcant differences in mean values between
the RSA and THA groups based on imputed data (ie,
incremental costs and QALYs), the analysis uses an OLS
regression within the STATA’s mim command.
Cost-effectiveness
Using the methods identiﬁed above, total costs and
QALY ﬁgures were calculated for all patients including
imputed data. For the cost-effectiveness analysis, we iden-
tiﬁed the differences between costs and QALYs between
the two arms, dividing the former by the latter to
compute an incremental cost-effectiveness ratio (ICER).
When compared against the marginal trade-off for the
NHS as a whole—the cost-effectiveness threshold—the
ICER gives a broad indication of whether spending add-
itional money on hip arthroplasty appears efﬁcient. The
ICER ﬁgure is not presented with a CI due to difﬁculties
in interpreting a ratio of two random variables. Instead,
we assume that each QALY is valued at £20 000 and sub-
tract costs from this ‘monetised’ QALY in order to
obtain a net monetary beneﬁt (NMB). Any treatment
with an ICER below £20 000 will have a positive NMB,
with higher NMB ﬁgures unambiguously better and
lower NMB ﬁgures unambiguously worse. As before, a
95% CI is formed for NMB using linear regression using
STATA’s mim command.
Scenarios/univariate sensitivity analyses
Key uncertainties in the scenarios considered were
explored using univariate sensitivity analyses. The results
for complete cost and quality-of-life data (ie, those with
no missing data) were provided to identify the impact of
missing data on the analysis. A strict per-protocol analysis
of the data is also used to reﬂect any sensitivity to proto-
col violations. A societal perspective was also explored by
adding the patient medicines and productivity costs out-
lined above to the NHS+PSS costs. As patients might
also recover function within the ﬁrst 3 months (rather
than continuously to 3 months), a quicker initial recov-
ery was explored in QALY calculations, where each
patient’s quality of life was assumed to reach its observed
3-month level at 6 weeks postoperatively. The cost
assumptions in the analysis were modiﬁed by assessing
the impact of assuming the least expensive (metal on
polyethylene) THA implant was used throughout with
no effect on observed outcomes, to reﬂect the potential
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concern that the THA arm might not reﬂect cost-
effective practice. The recent (after the trial) current
recommendations against the use of metal-on-metal
THA prostheses are brieﬂy considered by setting all
‘metal-on metal’ implants to missing, estimating which
THA prosthesis (ie, metal on polyethylene or ceramic
on ceramic) each patient will receive using multiple
imputation, and considering the cost implications within
these alternative estimates.
Adjustment for potential baseline differences
The base-case analysis was conducted to allow for com-
parability between this within-trial analysis and the
reporting of the main RCT.11 These quality-of-life and
gender-based analyses are conducted as sensitivity ana-
lyses to allow comparability with the main RCT, which
did not ﬁnd a signiﬁcant difference in baseline quality
of life and did not test for an interaction between efﬁ-
cacy and gender. Given that these issues may be import-
ant within the economic evaluation, they are considered
as sensitivity analyses.
The impact of potential baseline differences in quality
of life is corrected for using regression analysis within a
sensitivity analysis. The number of QALYs received
(average quality of life over 12 months) is assumed to be
a normal distribution, conditional on trial arm (RSA or
THA) and baseline EQ-5D-3L value. Total cost over
12 months is assumed to be lognormal, so that the
natural logarithm of costs is a normal distribution, con-
ditional on trial arm, baseline EQ-5D-3L.
QALYs and (log-)costs for each person are estimated
using ordinary least-squares regression (using STATA’s
mim command to handle imputed data). As any rela-
tionship between uncertainty in the extra costs and ben-
eﬁts associated with RSA is important when assessing the
likelihood of cost-effectiveness, we use a seemingly unre-
lated regression to do this. By using a Cholesky decom-
position of the variance–covariance matrix, (log-)costs
and QALYs are modelled as if they come from a multi-
variate normal distribution. Uncertainty in the value of
other items in the regression is ignored. From here,
costs are estimated as if all patients receive THA, and
incremental costs are calculated as a proportion of the
average THA cost. In this way, a distribution is built up
for incremental costs and incremental QALYs that can
be analysed using cost-effectiveness acceptability curve
(CEAC) can be formed for this analysis.20 This CEAC
indicates the likelihood that RSA will be cost-effective at
different ‘values’ for a QALY.
As gender so heavily affects the clinical use of RSA,
this analysis was rerun for both male patients only and
female patients only. This allows the effects of RSA to be
assessed separately for men and women, with this ﬁgure
presented as the likelihood of that RSA would be cost-
effective at a threshold value of £20 000 per QALY.
RESULTS
Trial recruitment
The trial11 recruited a total of 126 patients (RSA=60;
THA=66) between May 2007 to February 2010. Two
patients from each arm of the study did not have
surgery and provided only baseline quality-of-life/demo-
graphic data, leaving a total of 58 and 64 patients in
each arm. The sample was representative of the broader
population undergoing resurfacing in the UK during
the period of recruitment; no signiﬁcant differences
were identiﬁed between those who took part and those
who were eligible but chose not to take part. Further
details on both the ethical approval for the study and
the demographics of the patients are provided in the
clinical paper.11 As the analysis estimates data on costs
and outcomes conditional on baseline quality of life,
these patients cannot contribute any data to our analysis
and are excluded from the analyses here.
Quality of life
Table 1 summarises quality-of-life estimates at the four
time points and calculates QALY estimates both with and
without data imputation in the two arms. Overall, those
in the RSA group started in worse health (as measured by
the EQ-5D-3L) and received 0.033 more QALYs within
the 12 months of the trial (n=118 observations). When
the small amount of missing data is imputed, the esti-
mated beneﬁt remains very similar at 0.032 (95% CI
−0.054 to 0.119). Within the trial, the difference in
quality of life between the RSA and THA arms of the trial
appears to increase at each postoperative time point.
Table 1 EQ-5D-3L quality of life at each measurement and converted into quality-adjusted life-years (QALYs) (missing data
imputed)
Quality of life RSA (SD) n=58 THA (SD) n=64 Difference (95% CI)
Baseline 0.308 (0.338) 0.356 (0.335) −0.048 (−0.168 to 0.073)
3 months 0.722 (0.229) 0.698 (0.284) 0.023 (−0.711 to 0.118)
6 months 0.796 (0.244) 0.747 (0.287) 0.050 (−0.046 to 0.146)
12 months 0.795 (0.282) 0.727 (0.319) 0.067 (−0.042 to 0.177)
QALYs (n=118) 0.716 (0.216) 0.683 (0.252) 0.033 (−0.053 to 0.120)
QALYs* (n=122) 0.713 (0.216) 0.681 (0.251) 0.032 (−0.054 to 0.119)
*With imputed data.
RSA, resurfacing arthroplasty; THA, total hip arthroplasty.
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Costs and resource usage
Overall, NHS and social care costs were signiﬁcantly
higher among the RSA group with an average of £564
more spent within the ﬁrst 12 months from the oper-
ation (table 2), of which the majority is due to the
higher cost of implants and length of stay following the
initial operation (£184), subsequent inpatient care
(£279) and outpatient care (£84). The deﬂated cost of
the RSA implants including operative consumables used
in this study was £1826 versus an average of £1700 for
THA operations, based on imputed data. THA implants
differed in costs, with the most expensive being
ceramic-on-ceramic implants (£2042) and those using
metal-on-metal implants costing slightly less than RSA
implants (£1625). Implants and consumables in
metal-on-polyethylene operations (£843) were associated
with only 40% of the cost of ceramic-on-ceramic
implant. While the resurfacing implants were more
expensive, they were also associated with a slightly
longer length of stay (5.7 versus 5.5 days), although this
difference was not statistically signiﬁcant (p=0.536;
imputed data).
Those in the RSA arm had signiﬁcantly more out-
patient visits than those in the THA arm (5.155 versus
3.063, p=0.0054; non-imputed data). Here, both the
number of physiotherapy sessions and the use of deep
vein thrombosis assessments were signiﬁcantly higher
among this group (p=0.002, p=0.011; non-imputed
data). For inpatient care, only subsequent inpatient
attendances (0.155 versus 0.047, p=0.066; non-imputed
data) approached signiﬁcance, with the only signiﬁcant
difference (p=0.009) in aids and adaptations favouring
RSA. For full details on individual resource use items
and their unit costs, please see the tables available as a
Web Extra.
The private costs to patients following arthroplasty
surgery are considerable, although relatively little of this
is due to the purchase of medication. There are no sig-
niﬁcant differences in medication usage between the
RSA and THA arms, and the total costs of this treatment
is similar (£12 RSA versus £9 THA, p=0.667). RSA
patients report an average of 73 days off work, as against
57 days for THA patients (p=0.333). While surgery
results in a large number of days off work for the
patient, carers tend to take very few days off work
(2.1 days RSA versus 1.6 days THA; p=0.595). Overall,
RSA patients report costs valued at £5917, as against
£5853 in the THA arm (imputed data). This difference
is small but highly uncertain, such that there is no sig-
niﬁcant difference in costs from a societal perspective
(£629 higher costs in RSA, 95% CI −£2456 to £3713).
Cost-effectiveness and sensitivity analyses
While RSA is expected to cost more over the ﬁrst
12 months following an operation, it appears to provide
a difference in quality of life. Here, the incremental
ICER for RSA is £17 451 per QALY (£564/0.032 QALY).
Within most of the sensitivity tests explored here, the
ﬁgure appears to remain within or below the £20k–£30k
per QALY range used by the National Institute for
Health and Clinical Excellence as its estimate of the
cost-effectiveness threshold, except where cheaper THA
implants are used in place of surgeon’s preference,
which was mostly MOM THA within the trial (table 3). If
the cheaper (metal-on-polyethylene) implants are used,
the increased cost of RSA versus THA implants is
enough to raise the average cost difference above £1000
which, given the small quality-of-life difference observed
here, is enough to prevent RSA being cost-effective.
However, if we consider both types of non-MOM implants
(ceramic-on-ceramic and metal-on-polythene), this dif-
ference disappears entirely as the non-MOM implants
were slightly more expensive on average than the MOM
ones. The CI for net beneﬁt in every analysis spans zero
(table 4) so that the ﬁndings do not reach statistical sig-
niﬁcance. As clinical trials are very rarely designed with
the power of cost-effectiveness conclusions in mind, very
little can be inferred from this lack of signiﬁcance.
Adjustment for baseline differences
Once baseline differences in EQ-5D-3L are considered,
the QALY estimates for the ﬁrst 12 months appear to
change. QALYs are higher generally among those who are
healthier at baseline (EQ-5D-3L; p=0.000), with those
treated in the RSA arm receiving 0.053 more QALYs than
those treated with THA (p=0.119). Likewise, (log)-costs
Table 2 Costs by type, summed across trial period (missing data imputed)
Costs % Imputed RSA (SD) n=58 THA (SD) n=64 Difference (95% CI)
Initial operation/care 7 £6275 (557) £6091 (532) £184 (−18 to 386)
Subsequent inpatient 11 £470 (956) £191 (558) £279 (−11 to 569)
Outpatient 11 £360 (294) £276 (210) £84 (−13 to 181)
Primary/community 11 £63 (98) £49 (67) £14 (−17 to 45)
Aids and adaptations 11 £21 (33) £21 (40) £0 (−14 to 14)
Medication 11 £27 (43) £24 (41) £3 (−13 to 19)
NHS+PSS costs – £7217 (1320) £6653 (917) £564 (144 to 985)
Private costs 61 £5917 (5145) £5853 (5520) £64 (−3017 to 3146)
Societal cost – £13 134 (5146) £12 506 (5568) £629 (−2456 to 3713)
NHS, National Health Service; PSS, Personal Social Services; RSA, resurfacing arthroplasty; THA, total hip arthroplasty.
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appear to be affected by baseline health (p=0.034), with
costs 7.1% higher (95% CI 1.7% to 12.9%) for those who
received RSA after bootstrapping.
While correcting for baseline differences leaves the
incremental costs largely unchanged (£473; 95% CI: 107
to 840), the estimated QALY beneﬁt almost doubles
(0.053, 95% CI: −0.014 to 0.120). Consequently, the
ICER is around half as large (£8905 per QALY) as the
non-adjusted case. In 79% of cases investigated, RSA is
recommended when valuing health at £20 000 per
QALY—suggesting quite high conﬁdence that RSA is the
more cost-effective option within the ﬁrst 12 months of
treatment across the £20k–£30k range used by NICE
(ﬁgure 1). Where this analysis is rerun for male patients
only (n=71), neither incremental costs nor incremental
QALYs reach statistical signiﬁcance and the ICER falls to
£5519 per QALY. For female patients (n=51), the ICER
is about three times as large as for males (£16 272 per
QALY) due to higher costs and lower beneﬁts, with the
latter exacerbated by a much lower baseline quality of
life (female 0.257, male 0.389; p=0.032). Within the
scenarios used here, RSA is only 54% likely to be cost-
effective for female patients at £20 000 per QALY, com-
pared to an 86% likelihood for male patients.
DISCUSSION
In comparison with standard THA, hip RSA appears to
provide a modest QALY gain for a modest sum within
the ﬁrst 12 months from surgery; while the additional
costs of RSA are statistically signiﬁcant, the additional
beneﬁts are not. The higher costs of RSA treatments are
largely due to slightly higher costs for the initial opera-
tive and recovery periods, and higher usage of out-
patient services. While the RSA group achieves slightly
better health outcomes and requires more services, this
may be due to heterogeneity in outcomes; if resurfacing
works well for most but poor for some, then this could
produce this type of phenomenon. If so, this emphasises
the need to follow patients up in the longer term.
The analysis presented here analyses the data by consider-
ing potential confounding due to both gender and baseline
quality of life, and this nearly doubles the estimate of RSA
effect size. While the main analysis of the trial data11 found
no statistically signiﬁcant difference in hip function
between the RSA and THA groups at 12 months, it seems
likely that some short-term difference in quality of life exists
favouring RSA and that—again within 12 months—there is
enough evidence to suggest that it may be cost effective.
Within the ﬁrst 12 months of treatment, the main
caveat to our results deals with the comparator THA arm.
The pragmatic nature of the trial data used here11 is one
of its key strengths, since it reﬂects current practice. Any
changes to this practice may affect cost-effectiveness
though, so that RSA may become more/less cost-effective
as less/more cost-effective THA implants are used. A
recent (US) analysis of registry data suggests that more
expensive implants do not provide a substantive
age-adjusted advantage over less expensive prostheses.21
Where the sensitivity analysis assumed the use of the
cheapest metal-on-polyethylene implants (without
incorporating a possible impact on quality of life), RSA
was no longer cost-effective within-trial. However, these
implants were used relatively rarely in practice, and the
Table 3 Incremental cost effectiveness
Scenario Incremental costs (95% CI) Incremental QALYs (95% CI) ICER (per QALY)
Base case £564 (144 to 985) 0.032 (−0.054 to 0.119) £17 451
Per protocol £528 (85 to 970) 0.024 (−0.066 to 0.113) £22 227
Complete case data (N=98) £721 (286 to 1157) 0.053 (−0.042 to 0.149) £13 443
Societal costs £629 (−2456 to 3713) 0.032 (−0.054 to 0.119) £19 435
Metal/polyethylene THA implants £1271 (859 to 1684) 0.032 (−0.054 to 0.119) £39 318
No metal-on-metal THA implants £522 (76 to 968) 0.032 (−0.054 to 0.119) £16 137
Quicker initial recovery £564 (144 to 985) 0.039 (−0.048 to 0.127) £14 310
QoL adjustments £473 (113 to 853) 0.053 (−0.014 to 0.120) £8905
QoL adjustments, males only £402 (−82 to 916) 0.073 (−0.012 to 0.158) £5519
QoL adjustments, females only £598 (64 to 1172) 0.037 (−0.070 to 0.144) £16 272
ICER, incremental cost-effectiveness ratio; QoL, quality-of-life; THA, total hip arthroplasty.
Table 4 Net monetary benefit
Scenario NMB (95% CI)*
Base case £82.46 (−1795 to 1960)
Per protocol −£53 (−2011 to 1905)
Complete case data (N=98) £353 (−1719 to 2426)
Societal costs £19 (−3641 to 3680)
Metal/polyethylene THA
implants
−£625 (−2515 to 1265)
No metal-on-metal THA implants £125 (−1750 to 1999)
Quicker initial recovery £224 (−1658 to 2107)
Adjustments for quality of life £590 (−834 to 2014)
Adjustments for quality of life,
males
£1055 (−843 to 2954)
Adjustments for quality of life,
females
£137 (−1988 to 2262)
QALYs valued at £20k each.
NMB, net monetary benefit, THA, total hip arthroplasty.
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main alternative to metal-on-metal THA implants was the
more expensive ceramic on ceramic type. Restrictions in
the use of MOM THA implants within the UK are likely
to lead to more costly THA implants being used, and so a
net increase in the cost-effectiveness of resurfacing by
comparison.
Beyond the issues surrounding the choice of THA, the
trial is inevitably unable to consider all possible cost
items. The trial did not explicitly consider any differences
in operative time between the RSA and THA arms; no dif-
ference was expected and an informal analysis of the data
suggests very similar operative times between the arms.
This evaluation was also unable to consider the impact of
variation in cost within each type of prostheses (ie, within
the three types of THA, or beyond the single RSA used in
the trial) as this information is not generally available.
The clinical trial upon which this analysis is based used a
single type of Cormet prosthesis that has been used in
the UK for around 15 years. While the list price of the
Cormet prosthesis is similar to other prostheses available
locally, prices are hospital speciﬁc and so some caution is
warranted when seeking to generalise ﬁndings to other
locations. We note also that our ﬁndings are not necessar-
ily generalisable to other types of resurfacing, including
emerging technologies such as ceramic-on-ceramic resur-
facings. While the cost-effectiveness of these newer treat-
ments may differ from standard resurfacings, we cannot
identify the most cost-effective type of resurfacing as this
was beyond the scope of the trial and relatively little data
exists on which to base even a preliminary estimate. To
the degree that this may prove possible, it is an issue for
subsequent decision analytic modelling.
Clearly, the cost-effectiveness of resurfacing is likely to
require assessment over a longer period of time—as is
typically the case for any health economic analysis of trial
data.22 Importantly, the higher revision rates reported for
RSA suggest that the additional costs of RSA may be
higher if a longer period is considered. On the beneﬁt
side of the equation, the impact of extending the time
period is unclear as RSA may improve quality of life in
the short term but lead to a quicker deterioration once
revisions are necessary, or require additional monitoring
or revisions by virtue of its ‘MOM’ nature. One method
to explore these questions may be decision analytic mod-
elling.22 The trial provides an estimate of short-term clin-
ical beneﬁts from hip function and quality of life
(conditional on EQ-5D-3L), with longer follow-up series
(from trials or registry data) needed to model implant
survival for both RSA and THA.
As THA revision surgery may be surgically more
complex, ﬁnancially more costly and less effective than a
primary THA, a key question when interpreting this
study is the prognosis for patients after their RSA is
revised. An Australian registry analysis suggests poor
implant survival among patients receiving a revision of
only the acetabular RSA component, and some evidence
of higher revision risks among other types of RSA revi-
sions such as where both components are revised.23 It is
Figure 1 Cost-effectiveness acceptability curve for resurfacing arthroplasty
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unclear, however, as to whether a revised RSA is more
similar, in terms of quality of life, to a primary THA or a
revision THA. Further research is necessary to assess the
likely impact of this and other questions to guide future
research, and the ﬁndings of this paper are by no means
a complete answer to the decision problem.
Registry data reveal that women represent 61% of
primary THA patients in the UK but make up only 25% of
RSA patients.3 These ﬁgures reﬂect relevant gender differ-
ences from both a clinical and a health economic perspec-
tive as women appear to obtain higher quality-of-life gains
from THA, and face an increased revision rate from
RSA.4 24 This trial may also suggest a lower beneﬁt from
RSA relative to THA among women, although the ﬁnding
was not statistically signiﬁcant (or powered to be so).
Despite the conclusions of the within-trial analysis, it seems
clear that until such work is done and further data are
available, the cost-effectiveness of RSA in the UK context
remains potentially promising but as yet unproven.
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